one
hundr
year
past
sinc
ehrlich
langley
propos
exist
receptor
respons
cellular
compon
target
toxin
interplay
ligand
bind
cognat
receptor
mean
regul
cell
function
induc
prolifer
trigger
apoptosi
sinc
becom
fundament
understand
cell
biolog
immunolog
neurobiolog
well
ration
design
innov
therapeut
drug
lay
foundat
modern
pharmacolog
past
quarter
centuri
howev
paradigm
receptorligand
duo
revis
incorpor
third
player
scene
solubl
receptor
thu
creat
triad
protein
whose
balanc
regul
fine
tune
cellular
function
solubl
receptorsmolecular
decoy
first
propos
novel
biolog
envis
receptor
mimet
would
function
intercept
sequest
pathogen
solut
would
chanc
encount
cellular
target
howev
gene
clone
express
recombin
protein
genom
flourish
soon
becam
obviou
artifici
decoy
fact
lag
comparison
turn
natur
basic
modu
operandi
almost
everi
membran
receptor
cytokin
growth
factor
cell
adhesin
solubl
version
found
natur
produc
cell
henc
natur
decoy
function
modifi
potent
stimul
regul
inflamm
immun
respons
moreov
discov
decoy
receptor
hijack
virus
cours
coevolut
host
review
recombin
natur
molecular
decoy
describ
wherea
sugarbas
decoy
oligonucleotid
decoy
certainli
import
focu
primarili
proteinac
decoy
select
illustr
exampl
class
cell
regul
histor
justic
ehrlich
langley
antitoxin
antivir
decoy
first
discuss
move
natur
decoy
viral
hijack
version
end
exampl
biotech
pipelin
recombin
decoy
current
develop
product
provid
nicotin
acetylcholin
receptor
nachr
compos
five
polypeptid
subunit
bgd
mw
kda
togeth
form
ligandregul
ion
channel
neutrotoxin
dtubocurarin
cobra
toxin
antagonist
neurotransmitt
acetylcholin
whose
bind
open
channel
lead
membran
depolar
ultim
muscl
contract
ligand
overlay
protein
blot
prove
effect
delin
major
compon
cholinerg
bind
site
within
extracellular
domain
receptor
alpha
subunit
recombin
fusion
protein
express
ligand
bind
segment
alpha
subunit
found
effici
bind
alpha
neurotoxin
vitro
product
recombin
cholinerg
bind
site
ultim
test
vivo
found
protect
mice
lethal
dose
cobra
toxin
dtubocurarin
vivo
proof
principl
concept
decoy
propos
gener
applic
receptor
deriv
solubl
molecular
mimeticsdecoy
treatment
prevent
infecti
diseas
bacteri
toxin
often
mediat
morbid
death
sequestr
target
decoy
develop
case
point
clostridium
difficil
toxin
major
caus
antibiot
associ
diarrhoea
coliti
toxin
larg
protein
kda
bind
trisaccharid
sequenc
gala
galb
glcnac
display
lumin
surfac
apic
plasma
membran
intestin
epithelium
therefor
sugarbas
decoy
produc
test
canadian
biotech
compani
synsorb
biotech
conjug
trisaccharid
onto
inert
siliconbas
support
introduc
oral
rat
subsequ
subject
toxin
decoytr
rat
present
typic
toxin
associ
patholog
ileal
mucosa
compar
control
henc
decoy
abl
sequest
toxin
decoy
applic
particularli
attract
incid
antibiot
treatment
fact
detriment
antibiot
compromis
natur
flora
provid
clostridium
opportun
colon
telovam
solubl
high
molecular
weight
anion
polym
repres
function
decoy
abl
bind
neutral
toxin
toxin
b
clostridium
difficil
yet
deriv
natur
receptor
toxin
genzym
corp
announc
recent
phase
iii
clinic
studi
prove
less
effect
earlier
phase
ii
result
indic
yet
develop
pursu
anoth
exampl
decoy
becom
advantag
light
neg
effect
antibiot
treatment
hemolyticurem
syndrom
hu
caus
shiga
toxinproduc
e
coli
stec
infect
antibiot
therapi
case
contraind
lead
releas
cell
associ
shiga
toxin
stx
induc
toxin
gene
express
thu
lead
increas
free
toxin
gut
lumen
eleg
treatment
stec
infect
propos
paton
et
al
construct
recombin
probiot
e
coli
strain
display
stx
receptor
mimic
surfac
stx
bind
glycolipid
receptor
globtriaosyl
ceramid
structur
gala
galb
glc
ceramid
glycosyl
transferas
gene
igtc
igt
deriv
neisseria
introduc
e
coli
render
abl
produc
chimer
lipopolysaccharid
lp
core
termin
gala
galb
glc
probiot
bacteri
decoy
capabl
prevent
fatal
system
complic
stec
mice
treat
oral
administr
recombin
e
coli
threat
infecti
diseas
took
sinist
realiti
sinc
septemb
biowarfar
becom
ever
grow
concern
follow
two
exampl
antitoxin
decoy
thu
especi
relev
staphylococc
enterotoxin
b
seb
act
superantigen
indiscrimin
activ
broad
popul
cell
trigger
massiv
releas
inflammatori
cytokin
escal
toxic
shock
syndrom
death
mode
action
seb
bind
vb
region
cell
receptor
tcr
despit
rel
low
affin
seb
vb
kd
mm
potenc
toxin
high
lethal
dose
low
nanogram
per
kilogram
bodi
weight
buonpan
et
al
systemat
optim
murin
domain
use
serial
mutagenesi
yeastdisplay
follow
increasingli
stringent
screen
biotinyl
seb
highestaffin
mutant
isol
affin
pm
three
million
fold
improv
wild
type
interact
vb
decoy
prove
highli
effect
neutral
toxin
even
rabbit
alreadi
develop
earli
sign
toxic
shock
syndrom
illustr
power
decoy
emphas
efficaci
appar
directli
correl
affin
target
anthrax
toxin
certainli
play
major
role
arsen
bioterrorist
bacillu
anthraci
secret
tripartit
toxin
compos
protect
antigen
pa
kda
bind
macrophag
lethal
factor
lf
zinc
metalloproteinas
ca
calmodulindepend
adenyl
cyclas
call
edema
factor
ef
bind
integrinlik
domain
macrophag
surfac
protein
capillari
morphogenesi
protein
lead
cleavag
furin
endoproteas
produc
oligomer
heptam
provid
bind
site
lf
ef
endocytos
eventu
kill
cell
variou
approach
develop
counteract
anthrax
toxin
antipa
antibodi
proven
particularli
effect
concern
howev
weapon
strain
b
anthraci
may
engin
produc
antigen
alter
version
pa
would
escap
neutral
exist
antipa
antibodi
attribut
decoy
appar
one
assum
receptor
bind
surfac
pa
would
amen
mutagenesi
epitop
modif
scobi
et
al
abl
demonstr
solubl
function
potent
decoy
capabl
protect
rat
lethal
toxin
challeng
make
decoy
one
effect
anthrax
antitoxin
known
first
bona
fide
antivir
decoy
develop
solubl
treatment
aid
natur
integr
membran
glycoprotein
protein
travers
plasma
membran
extracellular
portion
compos
four
immunoglobulin
ig
domain
bind
fact
member
immunoglobulin
superfamili
profound
effect
develop
decoy
develop
decoy
gener
immunoglobulin
natur
present
membran
bound
cell
surfac
receptor
b
cell
receptor
bcr
yet
matur
solubl
serum
antibodi
result
altern
splice
antibodi
effici
antigen
recognit
cognat
membran
bound
bcr
isotyp
switch
fundament
antibodi
biolog
swap
v
domain
ig
domain
make
perfect
sens
moreov
antibodi
natur
polyval
bival
igg
tetraval
iga
decaval
igm
therefor
avid
binder
target
capon
et
al
first
engin
immunoadhesin
graft
ligand
bind
ig
domain
onto
human
fc
scaffold
prove
increas
serum
halflif
decoy
markedli
much
strategi
decoy
design
adopt
work
solubl
receptorsdecoy
gener
figur
despit
optim
howev
turn
decoy
simpli
clout
requir
keep
hiv
check
quickli
realiz
neutral
potenc
preferenti
greater
lab
adapt
strain
hiv
field
isol
viru
mechan
neutral
decoy
requir
induc
shed
turn
much
demand
field
isol
attempt
optim
improv
decoy
prove
insuffici
moment
decoy
progress
beyond
phase
iii
clinic
trial
sinc
introduct
aid
therapeut
solubl
receptor
variou
virus
eg
rhinoviru
polioviru
foot
mouth
diseas
viru
sar
coronaviru
hepat
viru
report
neutral
activ
thu
form
basi
novel
therapeut
howev
date
commerci
decoyproduct
effect
prevent
treatment
viral
infect
still
appear
market
may
due
fact
virus
replic
pathogen
demand
enorm
effici
viral
clearanc
order
decoy
truli
therapeut
decoy
modifi
regul
contrari
turn
natur
compon
fine
tune
inflamm
immun
respons
ullrich
et
al
publish
clone
human
epiderm
growth
factor
receptor
egfr
mw
kda
epidermoid
carcinoma
cell
curious
also
discov
cell
contain
kb
mrna
express
produc
kda
truncat
version
egf
extracellular
domain
author
conclud
particularli
intrigu
view
earlier
observ
verbb
oncogen
encod
seem
truncat
avian
receptor
polypeptid
correspond
transmembran
cytoplasm
domain
thu
focu
motiv
neutral
solubl
receptor
rather
truncat
constitut
signal
transduc
receptor
could
explain
outofcontrol
cell
prolifer
associ
cancer
nonetheless
shortli
report
appear
describ
divers
natur
exist
solubl
receptor
could
associ
one
two
gene
famili
tumour
necrosi
factor
tnf
superfamili
ig
superfamili
immedi
becam
appar
proteolyt
shed
cell
surfac
protein
metalloproteas
coin
sheddas
altern
splice
truncat
version
otherwis
membran
associ
receptor
readili
gener
natur
produc
solubl
receptor
order
crucial
regul
immun
respons
toward
cancer
infect
well
inflamm
gener
figur
mantovani
colleagu
pioneer
concept
natur
decoy
receptor
natur
solut
fine
tune
potent
defens
mechan
specif
exampl
solubl
interleukin
receptor
type
ii
illustr
case
point
interleukin
one
first
cytokin
discov
respons
trigger
divers
physiolog
effect
fever
augment
lymphocyt
respons
induct
degen
chang
joint
owe
divers
even
question
whether
singl
molecul
could
respons
varieti
function
ultim
clone
laid
debat
rest
becam
clear
cytokin
function
master
switch
sort
respons
express
releas
numer
cytokin
eg
mani
chemokin
avail
recombin
also
promptli
led
discoveri
receptor
first
type
member
ig
superfamili
contain
three
iglik
extracellular
domain
signal
tranduc
tolllik
cytoplasm
domain
receptor
express
cell
function
complex
associ
proteinacp
second
type
ii
express
primarili
b
cell
monocyt
polymorphonuclear
cell
pmn
also
exist
yet
unabl
signal
transduc
cytoplasm
tail
long
colotta
et
al
abl
show
type
ii
function
decoy
receptor
present
membran
associ
solubl
form
furthermor
express
regul
togeth
illustr
complex
elabor
regulatori
devic
exist
control
respons
action
mediat
associ
type
moder
sequestr
cytokin
solubl
type
ii
upregul
moreov
type
ii
also
bind
acp
effect
bind
decoy
type
ii
ilr
type
iacp
caus
domin
neg
shut
signal
transduct
solubl
decoy
receptor
alway
antagonist
ligand
illustr
solubl
receptor
decoy
bind
prolong
halflif
furthermor
bind
membran
bound
trigger
signal
transduct
via
process
transsign
final
decoy
action
mediat
membran
bound
receptor
well
particularli
relev
chemokin
receptor
whose
decoy
persist
membran
protein
effect
ligand
bind
handicap
signal
transduct
thu
dud
receptor
serv
function
decoy
fine
tune
inflamm
figur
strategi
also
employ
regul
program
cell
death
mediat
death
receptor
decoy
decoy
receptor
membran
bound
dud
receptor
unabl
signal
transduc
decoy
receptor
howev
potent
solubl
decoy
fa
ligand
tend
overexpress
variou
cancer
illustr
tip
balanc
regul
apoptosi
profound
effect
cancer
pathogenesi
see
figur
molecular
decoy
antidot
therapeut
immunomodul
gershoni
nativ
receptor
decoy
bind
ligand
nativ
receptor
trigger
signal
transduct
cascad
cytokin
chemokin
growth
factor
often
toxin
virus
exploit
exist
receptor
altern
ligand
therebi
elicit
morbid
gain
entri
cell
order
prevent
toxin
viral
pathogenesi
modifi
effect
natur
ligand
decoy
intercept
ligand
reach
nativ
receptor
three
type
decoy
portray
dud
receptor
membran
associ
decoy
bind
nativ
ligand
yet
unabl
signal
transduc
solubl
receptor
produc
natur
either
altern
splice
proteolyt
cleavag
recombin
solubl
receptor
provid
research
tool
lead
develop
novel
pharmaceut
prefer
modal
therapeut
decoy
immunoadhesin
receptor
bind
domain
graft
onto
fc
scaffold
surpris
abil
interven
immunoregulatori
process
decoy
receptor
exploit
larg
dna
virus
thu
creat
viroceptor
poxvirus
produc
divers
solubl
cytokin
receptor
well
version
cytokin
bind
protein
viral
decoy
receptor
tnf
interferon
g
ifng
provid
poxvirus
mean
counter
act
evad
immun
respons
contribut
directli
virul
viru
thu
exampl
delet
viral
ifng
bind
protein
effect
viral
replic
cell
cultur
yet
dampen
virul
dramat
vivo
point
might
import
design
safer
vaccin
viral
decoy
receptor
delet
render
toler
viru
without
compromis
antigen
repertoir
viral
decoy
although
deriv
host
receptor
evolv
enhanc
activ
immun
evas
thu
exampl
vaccinia
viral
receptor
tend
much
specif
mammalian
cell
homologu
viral
ifngr
highli
stringent
host
opposit
occur
broadli
cross
reactiv
solubl
viral
decoy
decoy
may
actual
result
captur
receptor
domain
host
also
helixturnhelix
hth
deriv
tfiia
host
transcript
factor
transcript
factor
hth
domain
allow
oligomer
structur
element
enabl
viral
decoy
form
tetram
thu
benefit
avid
bind
multidomain
natur
viral
decoy
found
vtnfr
well
pox
tnfr
code
four
gene
name
cytokin
respons
modifi
b
crmb
crmc
crmd
crme
crmb
addit
tnf
bind
domain
carboxi
terminu
develop
capac
bind
chemokin
thu
crmb
simultan
sequest
tnf
bind
chemokin
well
chemokin
bind
receptor
particularli
well
develop
herp
virus
case
point
human
cytomegaloviru
hcmv
open
read
frame
close
homolog
cc
chemokin
receptor
bind
cc
chemokin
nanomolar
rang
wherea
effect
chemokin
sequestr
express
requir
viral
replic
cultur
cell
contrari
membran
bound
receptor
may
differ
role
may
enabl
virusinfect
cell
follow
natur
chemokin
gradient
thu
assist
dissemin
cell
prefer
tissu
host
viroceptor
interplay
virus
host
may
actual
provid
new
insight
design
futur
therapi
undoubtedli
concept
exploit
ligand
bind
domain
receptor
lead
therapeut
decoy
extrem
attract
howev
fact
moment
decoy
fda
approv
bona
fide
commerci
viabl
product
nonetheless
progress
effort
greatest
promis
seem
counter
act
chronic
inflamm
treat
cancer
tumour
necrosi
factor
tnf
central
proinflammatori
cytokin
trigger
product
mediat
inflamm
tissu
destruct
tnf
directli
associ
diseas
chronic
sever
inflamm
rheumatoid
arthriti
ra
crohn
diseas
psoriasi
therefor
target
product
specif
therapeut
antagonist
etanercept
enbrel
market
amgen
wyeth
dimer
immunoadhesin
see
consist
extracellular
ligand
bind
domain
tnf
receptor
link
fc
scaffold
contrast
two
antagonist
base
tnfspecif
monoclon
antibodi
infliximab
adalimumab
etanercept
bind
tnfa
lymphotoxin
formerli
tnfb
thu
illustr
advantag
decoy
antibodi
tend
restrict
bind
etanercept
also
show
higher
potenc
ra
therapi
although
seem
effect
antibodi
treatment
crohn
diseas
see
also
certainli
numer
label
indic
current
evalu
drug
prove
extrem
import
treatment
inflammatori
diseas
may
find
applic
treatment
cancer
well
inde
cancer
appear
directli
associ
chronic
inflamm
chronic
inflammatori
bowel
diseas
exampl
often
prelud
colon
cancer
recent
studi
popivanova
et
al
sequestr
tnf
shown
reduc
develop
colorect
cancer
mous
model
ulcer
coliti
treatment
mice
etanercept
markedli
reduc
progress
colorect
cancer
extend
surviv
dramat
result
demonstr
associ
tnf
mediat
inflamm
colon
cancer
potenti
use
etanercept
anticanc
drug
tumour
vascular
pivot
step
progress
metastat
cancer
long
tumour
hookedup
vasculatur
oxygen
nutrient
limit
growth
restrict
shed
malign
cell
abl
seed
organ
possibl
folkman
first
propos
antiangiogen
drug
treatment
solid
tumour
inde
central
target
drug
develop
regul
angiogenesi
vascular
endotheli
growth
factor
vegf
vegf
exist
number
molecular
variant
relat
factor
placent
growth
factor
elicit
effect
bind
receptor
first
biolog
fda
approv
antivegf
cancer
therapeut
monoclon
antibodi
bevacizumab
avastin
sinc
highli
potent
vegf
decoy
vegf
trap
aflibercept
develop
regeneron
pharmaceut
sanofiaventi
produc
vegftrap
recombin
immunoadhesin
compos
ig
domain
link
ig
domain
fuse
fc
thu
creat
dimer
decoy
preclin
mous
model
nonsmal
cell
lung
cancer
renal
cell
cancer
vegftrap
proven
substanti
potent
bevacizumab
view
result
vegftrap
current
subject
four
phase
iii
clinic
studi
patient
nonsmal
cell
lung
cancer
pancreat
cancer
colorect
cancer
prostrat
cancer
decoy
receptor
clearli
basic
compon
regulatori
machineri
cell
function
fine
tune
prolifer
death
cell
especi
immun
respons
also
play
role
immun
evas
virus
basic
concept
recombin
solubl
receptor
potent
therapeut
actual
preced
realiz
exist
natur
homologu
decoy
neutral
toxin
appear
effect
provid
genuin
biolog
antidot
prospect
antivir
seem
complex
demand
steril
effici
moment
beyond
potenc
exist
decoy
markedli
increas
affin
decoy
cognat
virus
might
necessari
make
class
therapeut
effect
moment
greatest
success
decoy
biolog
drug
immunoadhesin
variant
natur
cell
regul
tnf
vegf
similar
product
cytotox
tlymphocyt
associ
antigen
also
approv
indic
see
multipl
decoy
market
near
futur
